KEYNOTE-052: 5-Yr Update of First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.
Format: Microsoft PowerPoint (.ppt)
File Size: 478 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Experts highlight key studies being presented at the upcoming 2021 ESMO Congress in this commentary from Clinical Care Options (CCO)

person default Eva Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Released: September 15, 2021

A downloadable slideset on new approaches to managing low-grade upper tract urothelial cancer from Clinical Care Options (CCO).

Surena Matin, MD Released: September 10, 2021

Slides from Clinical Care Options (CCO) on 2021 treatment recommendations for patients with nmCRPC.

David F. Penson, MD Released: September 10, 2021

A downloadable slideset from Clinical Care Options (CCO) focused on the latest evidence for managing non-muscle invasive bladder cancer (NMIBC).

Seth P. Lerner, MD Released: September 10, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue